Before today's opening bell, the Bloomsbury, NJ-based biopharmaceutical company posted a net loss of 33 cents per share, which was narrower than the loss of 35 cents per share that analysts were expecting.
Revenue for the period was $1.79 million, beating Wall Street's estimates of $0.7 million.
Revenue was helped by the company's clinical trial collaboration with Bristol-Myers Squibb (BMY) and its research and development agreement with Rockefeller University, Celldex said.
"2015 was a year of considerable progress for Celldex and our growing pipeline," President and CEO Anthony Marucci said in a statement.
"Most importantly, we completed the Phase 2 ReACT Study of RINTEGA in recurrent GBM, confirming a highly statistically significant long-term overall survival benefit," he added.
Rintenga is the company's cancer immunotherapy.
Celldex is focused on the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by some concerns, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: CLDX